Immunotherapy success for triple-negative breast cancer
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...
List view / Grid view
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
The onset of side effects of a common cancer treatment, anti-PD-1 therapy can be identified up to 3 years after treatment...
Children with an extremely deadly form of brain cancer may benefit from a new treatment that aims to direct an immune response against an abnormally shaped protein found on cancer cells...
TLR agonists injected directly into a tumour suppresses tumour growth throughout the whole body...
Investigational therapy directly kills tumour cells and unmasks them to the body's defences.
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects...
28 October 2016 | By Dolomite Bio
Dolomite Bio’s Single Cell RNA-Seq System is helping researchers at the University of Helsinki to investigate autoimmune diseases. Focusing on gastrointestinal conditions – such as coeliac disease and inflammatory bowel disease – the Molecular Genetics of Immunological Diseases group is using the system to study T-cell activation and response at…
Vaximm's VXM01 is an oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells...
11 July 2016 | By Victoria White, Digital Content Producer
This license agreement opens new markets to Celyad and expands the global footprint of its NKR-2 T-cell cancer immunotherapy treatment...
23 June 2016 | By Victoria White, Digital Content Producer
The study is evaluating Celyad's NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma...
21 June 2016 | By Victoria White, Digital Content Producer
The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL...
26 May 2016 | By Victoria White, Digital Content Producer
Celyad has completed the safety follow-up of the third dose level cohort in its Phase I/IIa clinical trial of its NKR-2 T-cell therapy...